Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 0.49 |
| ▸ | PNMT | P11086 | 4/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HTR5A | P47898 | 1/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.46 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2562691 | 0.85 | PNMT (0.58) | CD44PNMTMAOBTAAR1PARP1 | |
| SCHEMBL1938502 | 0.82 | LMNA (0.46) | PNMTLMNA | |
| SCHEMBL54652 | 0.76 | ALDH1A1 (0.50) | KDM4ELMNA | |
| SCHEMBL29481017 | 0.76 | ALDH1A1 (0.50) | KDM4ELMNA | |
| SCHEMBL9094448 | 0.74 | LMNA (0.40) | PNMTKDM4ELMNA | |
| SCHEMBL11629542 | 0.73 | CD44 (0.47) | CD44PNMTMAOBKDM4EHTR5A | |
| SCHEMBL29508231 | 0.72 | HSD17B10 (0.46) | KDM4E | |
| SCHEMBL4298702 | 0.72 | HSD17B10 (0.46) | HTR5ANISCHLMNA | |
| SCHEMBL322439 | 0.72 | KIF11 (0.49) | KDM4E | |
| SCHEMBL29853815 | 0.72 | KIF11 (0.49) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058954-A1 | Diaza Heterocyclic Compounds for Phototherapy | OCERA THERAPEUTICS LLC | 2012-03-08 | — | — | US | disclosed |
| EP-0750614-B1 | QUINAZOLINYL-AMINO DERIVATIVES HAVING ALPHA-ANTAGONIST ACTIVITY | RECORDATI CHEM PHARM (CH) | 2001-05-23 | — | — | EP | disclosed |
| EP-1021415-A1 | TRICYCLIC AMINOALKYLCARBOXAMIDES; NOVEL DOPAMINE D 3? RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-07-26 | — | — | EP | disclosed |
| US-5910586-A | Tricyclic aminoalkylcarboxamides; dopamine D3 receptor subtype specific ligands | NEUROGEN CORPORATION (US) | 1999-06-08 | — | — | US | disclosed |
| US-5798362-A | USEFUL AS ALPHA-ADRENORECEPTOR BLOCKERS; CONDENSATION | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1998-08-25 | — | — | US | disclosed |
| US-5688950-A | NERVOUS SYSTEM DISORDERS, SIDE EFFECT REDUCTION | NEUROGEN CORPORATION (US) | 1997-11-18 | — | — | US | disclosed |
| WO-1997040015-A1 | TRICYCLIC AMINOALKYLCARBOXAMIDES; NOVEL DOPAMINE D3 RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1997-10-30 | — | — | WO | disclosed |
| EP-0803505-A1 | Inhibitors of metalloproteases, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1997-10-29 | — | — | EP | disclosed |
| EP-0750614-A1 | QUINAZOLINYL-AMINO DERIVATIVES HAVING ALPHA-ANTAGONIST ACTIVITY | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1997-01-02 | — | — | EP | disclosed |
| WO-1995025726-A1 | QUINAZOLINYL-AMINO DERIVATIVES HAVING α-ANTAGONIST ACTIVITY | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1995-09-28 | — | — | WO | disclosed |
| US-4824852-A | Substituted indole compounds which have useful effects on the central nervous system | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-04-25 | — | — | US | disclosed |
| US-4740602-A | Indole derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-04-26 | — | — | US | disclosed |
| EP-0206225-A2 | Indole derivatives | MERCK PATENT GmbH (DE) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058954-A1 | Diaza Heterocyclic Compounds for Phototherapy | BAD, BID, CASP3 | CD44 3095/4885PNMT 2317/4885MAOB 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.